Molbreevi (molgramostim)
Savara (SVRA)
Decision dateNov 22, 2026
7 days away
Marketer take
Rare pulmonary launch; the review was already extended three months, so plan launch materials with date-slip contingency.
- Sponsor company
- Savara (SVRA)
- Indication
- Autoimmune pulmonary alveolar proteinosis (aPAP)
- Therapeutic area
- Pulmonology, Rare disease
- Event
- PDUFA target action date
- Date
- Nov 22, 2026
- Status
- Delayed
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?